Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11786589
Human rotavirus strains and vaccines
granted -
US 11786605
Site specific antibody-drug conjugates with peptide-containing linkers
granted -
US 11786536
Salts of potassium ATP channel openers and uses thereof
granted -
US 11786553
Chimeric cytokine receptors bearing a PD-1 ectodomain
granted -
US 11786464
PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related proteins
granted -
US 11790574
System and method for carbon dioxide angiographic roadmap imaging
granted -
US 11788141
MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
granted -
US 11787840
Compositions and methods for treating and preventing autoimmune induced cardiac long QT syndrome
granted -
US 11788077
Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 11787869
Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness
granted -
US 11787867
Anti-GITR antibodies and uses thereof
granted -
CA 3255134
COMPOSITION D'ALLERGÈNE D'ARACHIDE
granted -
US 11793812
Methods of treating endometriosis
granted -
US 11793780
Prodrugs of treprosiinil
granted -
US 11793815
Oxindoles and methods of use thereof
granted -
US 11793806
Pyruvate kinase activators for use in therapy
granted -
US 11793855
TFPI inhibitors and methods of use
granted -
US 11793871
Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
granted -
US 11793825
Biomarkers for predicting responsiveness to decitabine therapy
granted -
US 11793870
Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
granted -
US 11795443
Uses of adenosine base editors
granted -
US 11795192
Antimicrobial compounds, compositions, and uses thereof
granted -
US 11795130
Process for separating a constituent/cannabinoid using a chromatographic resin
granted -
US 11793912
Cross-linked fatty acid-based biomaterials
granted -
US 11795156
Bicyclic carboxamides and methods of use thereof
granted -
US 11795216
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
granted -
US 11795232
Engineered transferrin receptor binding polypeptides
granted -
US 11795233
Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide
granted -
US 11795234
Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide
granted -
US 11795457
Compositions and methods for treatment of Friedreich's Ataxia
granted -
US 11795235
Immunotoxins with albumin binding domain
granted -
US 11793860
Vault complexes for cytokine delivery
granted -
US 11793772
Pharmaceutical composition comprising THA as active ingredient for treating breast cancer
granted -
US 11795176
Solid forms of Alpha-1062 gluconate
granted -
US 11793776
Methods of administering solriamfetol to lactating women
granted -
US 11793888
Methods and compositions for engineering immunity
granted -
US 11793810
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
granted -
US 11793177
Animal model of Angelman Syndrome
granted -
US 11793796
Inhibition of crystal growth of roflumilast
granted -
US 11793819
Natural combination hormone replacement formulations and therapies
granted -
US 11793777
Methods and compositions for treating conditions associated with an abnormal inflammatory response
granted -
US 11793816
Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B
granted -
US 11795180
Formulation of a pan-JAK inhibitor
granted -
US 11795215
Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
granted -
US 11795434
Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof
granted -
CA 3249631
PROCÉDÉS ET COMPOSITIONS POUR RALENTIR LE DÉVELOPPEMENT DU DIABÈTE OU RÉDUIRE UN RISQUE DE DIABÈTE
granted -
US 11801241
Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline
granted -
US 11802158
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.